

Tomasz Sewastianik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9385503/publications.pdf>

Version: 2024-02-01

39
papers

775
citations

759233

12
h-index

526287

27
g-index

39
all docs

39
docs citations

39
times ranked

1900
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. <i>Cell</i> , 2018, 175, 101-116.e25. | 28.9 | 234 |
| 2 | Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy. <i>ACS Nano</i> , 2018, 12, 912-931. | 14.6 | 107 |
| 3 | Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. <i>Blood Cancer Discovery</i> , 2021, 2, 468-483. | 5.0 | 64 |
| 4 | FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. <i>Blood</i> , 2016, 127, 739-748. | 1.4 | 54 |
| 5 | MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 457-467. | 7.4 | 42 |
| 6 | Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 1418-1429. | 1.4 | 42 |
| 7 | BCL9 provides multi-cellular communication properties in colorectal cancer by interacting with paraspeckle proteins. <i>Nature Communications</i> , 2020, 11, 19. | 12.8 | 27 |
| 8 | A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. <i>Cancer Cell</i> , 2021, 39, 380-393.e8. | 16.8 | 27 |
| 9 | MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>PLoS ONE</i> , 2016, 11, e0155893. | 2.5 | 26 |
| 10 | A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 16917-16931. | 1.8 | 25 |
| 11 | Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. <i>Blood Advances</i> , 2019, 3, 3360-3374. | 5.2 | 25 |
| 12 | Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3548-3559. | 3.6 | 17 |
| 13 | MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells. <i>Experimental Hematology</i> , 2017, 46, 56-61.e1. | 0.4 | 13 |
| 14 | Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. <i>Blood Advances</i> , 2017, 1, 2361-2374. | 5.2 | 11 |
| 15 | ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. <i>Science Advances</i> , 2021, 7, . | 10.3 | 11 |
| 16 | A novel β -catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer. <i>Science Advances</i> , 2022, 8, eabm3108. | 10.3 | 10 |
| 17 | <i>miR-15a/16-1</i> deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. <i>Blood</i> , 2021, 137, 1905-1919. | 1.4 | 8 |
| 18 | ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. <i>Blood Cancer Discovery</i> , 2021, 2, 338-353. | 5.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | MiR-155 Amplifies AKT and NFκB Signaling By Targeting Multiple Regulators of BCR Signal in DLBCL. Blood, 2015, 126, 2455-2455. | 1.4 | 6 |
| 20 | Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Advances, 2020, 4, 5089-5092. | 5.2 | 5 |
| 21 | Microenvironment-Induced Expression of PIM Kinases Supports Chronic Lymphocytic Leukemia Cells Survival and Promotes CXCR4-mTOR Pathway Dependent Migration. Blood, 2016, 128, 3239-3239. | 1.4 | 4 |
| 22 | Abstract 1749: Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies. Cancer Research, 2014, 74, 1749-1749. | 0.9 | 2 |
| 23 | A Novel Pan-PIM Kinase Inhibitor, SEL24-B489, Induces Apoptosis and Inhibits Proliferation of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation of Myc and NFκB Activity. Blood, 2015, 126, 706-706. | 1.4 | 2 |
| 24 | Downregulation of Deptor By MiR-155 Promotes Cell Survival through Activation of PI3K/AKT and NFκB Signaling in ABC-Type Diffuse Large B-Cell Lymphomas. Blood, 2016, 128, 1761-1761. | 1.4 | 2 |
| 25 | FOXO1-p300-Txn Circuit Regulates Oxidative Stress Responses in Diffuse Large B-Cell Lymphomas Characterized By Enhanced Oxidative Phosphorylation. Blood, 2015, 126, 466-466. | 1.4 | 1 |
| 26 | Abstract 5394: First-in-class dual PIM/FLT3 kinase inhibitor SEL24-B489 for the treatment of hematological malignancies. Cancer Research, 2015, 75, 5394-5394. | 0.9 | 1 |
| 27 | Multiplexed CRISPR <i>In Vivo</i> Editing of CLL Loss-of-Function Lesions Models Transformation of Chronic Lymphocytic Leukemia into Richter's Syndrome. Blood, 2020, 136, 2-3. | 1.4 | 1 |
| 28 | Oncogenic activity of human MYD88L265P mutation in mature B-cells in vivo. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e331. | 0.4 | 0 |
| 29 | HIF1-Alpha and MYC Transcription Factor Signatures in B-Cell Acute Lymphoblastic Leukemia Are Associated with Positive Minimal Residual Disease Status: Therapeutic Implications. Blood, 2015, 126, 1436-1436. | 1.4 | 0 |
| 30 | Activity of PIM Kinases in Chronic Lymphocytic Leukemia Modulates Tumor Cell Survival and Stromal Interactions through a Pleiotropic Mechanism Involving Modulation of CXCR4 - mTOR Pathway. Blood, 2015, 126, 1549-1549. | 1.4 | 0 |
| 31 | Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma. Blood, 2015, 126, 819-819. | 1.4 | 0 |
| 32 | MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. Blood, 2015, 126, 4917-4917. | 1.4 | 0 |
| 33 | Functional Link Between Heat Shock Protein HSP90α and Sirtuin 1 (SIRT1) in the Pathogenesis of Diffuse Large B Cell Lymphoma. Blood, 2016, 128, 4120-4120. | 1.4 | 0 |
| 34 | Germinal Center-Derived Lymphomas and Plasmacytomas in Mice with Targeted Deletion of MiR-15a/16-1 in Activated B Cells. Blood, 2016, 128, 743-743. | 1.4 | 0 |
| 35 | Overexpression of BCL9, a Wnt/β ² -Catenin Transcriptional Co-Activator, in Transgenic Mice Promotes Spontaneous Development of B-Cell Malignancies. Blood, 2016, 128, 441-441. | 1.4 | 0 |
| 36 | Abstract 4087: Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of heme malignancies. , 2017, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | B Cell Restricted Expression of Mutated IKZF3 modulates BCR Signaling and Homing Pathways in a Mouse Model of CLL. <i>Blood</i> , 2019, 134, 848-848. | 1.4 | 0 |
| 38 | Aggressive CD4/CD8 Double-Negative Primary Cutaneous T-Cell Lymphoma With Dural Invasion: A Rare Presentation of Mycosis Fungoides?. <i>American Journal of Dermatopathology</i> , 2021, 43, 63-66. | 0.6 | 0 |
| 39 | <i>The ERK1/2 Regulator WNK2 Shows Differential Expression and Isoform Usage, Primarily Driven By Aberrant Methylation, in MYD88 Mutated Waldenström's Macroglobulinemia</i> . <i>Blood</i> , 2021, 138, 2692-2692. | 1.4 | 0 |